Onapgo is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in patients with advanced disease.
On January 7, 2025, the U.S. Food and Drug Administration (“FDA” or “Agency”) released a long-awaited guidance titled, “Communications From Firms ...
President Sheinbaum shared a plan to strengthen Mexico's semiconductor industry and touched on GMO corn and the U.S. DEA on ...
The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such ...
Fractures and breakages of the helix on the Rotarex system has led to 30 serious injuries, four deaths, and 115 interventions ...
Engineered to specifically act on the vascular endothelial growth factor receptor 2 (VEGFR2), BR55 (perfluorobutane/nitrogen ...
2d
These days, many devices are programmed through apps on patients’ phones. But the FDA warns that certain phone settings, such ...
The stop-work order on U.S.A.I.D.-funded research has left thousands of people with experimental drugs and devices in their ...
For more than a decade, the Food and Drug Administration (FDA) has made diversity in clinical trials a focus, including by issuing guidance, ...
The U.S. Food and Drug Administration has issued an urgent recall for the JMCC5A Ni/TruAire-5 Oxygen Concentrator due to the device spontaneously catching fire.
Smart watches, rings, and a growing array of patches are adding more functionality and being used across a growing set of ...
The Food and Drug Administration is warning that critical alerts from diabetes devices may fail to reach users, risking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback